Prospective Follow-up After MVA-BN Booster Vaccination

NCT ID: NCT07342829

Last Updated: 2026-01-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

95 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-01-15

Study Completion Date

2028-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

POQS-Boosted is a prospective observational study during which individuals who received Booster vaccination against mpox with the MVA-BN vaccine will be invited to provide biological samples at multiple times over the course of two years.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Mpox caused a worldwide outbreak in 2022 and continues to circulate worldwide and causes sporadic cases in Belgium and elsewhere. In the last 10 days, the first cases infected with the probably more virulent clade Ib MPXV have been reported from men who have sex with men in Belgium, the Netherlands, and elsewhere, indicating circulating this viral clade in sexual networks. In Belgium, vaccination against mpox was ceased at the end of 2022 and evidence showed that antibody levels against MPXV have decreased since then, raising questions about sustained protectiveness and the potential for a new mpox outbreak to emerge.

POQS-Boosted is a prospective observational study during which individuals who received Booster vaccination against mpox with the MVA-BN vaccine will be invited to provide biological samples at multiple times over the course of two years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Monkeypox (Mpox)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Is scheduled to receive a booster dose of MVA-BN
2. ≥18 years
3. Willingness to provide written informed consent
4. Willingness to follow the study schedule

Exclusion Criteria

1\. Past or current MPXV infection
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institute of Tropical Medicine, Belgium

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Laurens Liesenborghs, MD

Role: PRINCIPAL_INVESTIGATOR

Institute of Tropical Medicine Antwerp

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institute of Tropical Medicine

Antwerp, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Christophe Van Dijck, PhD

Role: CONTACT

+32 3 345 58 65

Clinical Trials Unit Antwerp

Role: CONTACT

+32 3 247 66 66

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

POQS-Boosted

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Evaluating the Human Immune Response to the JYNNEOS Vaccine
NCT06366672 ACTIVE_NOT_RECRUITING EARLY_PHASE1
Combination Study With MVA BN and Dryvax
NCT00082446 COMPLETED PHASE1